Option Care Health (OPCH) is back in focus after fresh commentary compared its home and alternate site infusion business with BrightSpring Health Services, highlighting how both could benefit as complex treatments continue shifting into lower cost home settings.

Recent trading tells a mixed story. Option Care Health’s share price is up 8.41% over the past 90 days but down 29.25% year to date, while the 1 year total shareholder return has declined 17.83%, which may hint at fading momentum despite the latest commentary on home based care.

Spot 35 healthcare AI stocks that, like Option Care Health, are positioned around complex care shifting into home settings and could be gearing up for their next major move.

After a sharp drop this year and a modest 90 day rebound, Option Care Health now sits in a grey zone. Is the meaningful upside still ahead, or did most of the easy gain already pass by?

Most Popular Narrative: 20.2% Undervalued

Against a last close of $22.81, the most followed narrative pegs Option Care Health’s fair value at $28.58, framing today’s pricing as a discount that leans on the durability of specialty infusion demand and payer relationships.

Growth in both acute and chronic infusion therapies is outpacing the market, driven by demographic shifts (aging population and higher prevalence of chronic/complex conditions). This is expanding Option Care Health’s addressable market and positioning the company for sustained revenue growth.

Deepening partnerships with national payers and pharmaceutical manufacturers, supported by system-wide shifts to lower-cost, value-based care and payers’ focus on medical loss ratios, are enhancing contract wins and broadening patient access, supporting revenue growth and pricing power.

See why 3 investors see Option Care Health as 20% undervalued.

Result: Fair Value of $28.58 (UNDERVALUED)

Still, if payer relationships tighten or therapy mix shifts further toward lower margin drugs, the bullish Option Care Health narrative could quickly look far more fragile.

Find out about the key risks to this Option Care Health narrative.

Another View: Option Care Health Through A Cash Flow Lens

The narrative around Option Care Health leans on a fair value of $28.58, yet the SWS DCF model tells a different story. On that framework, OPCH at $22.81 sits above an estimated future cash flow value of about $18.15, which screens as overvalued rather than discounted.

Two methods, one stock, and a wide gap in implied worth raise a basic question for investors: Which do you trust more, analyst earnings assumptions or a stricter cash flow test that bakes in less forgiving expectations?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

Mixed messages so far on Option Care Health and its valuation story. Act while the data is fresh and pressure test both sides by reviewing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Option Care Health?

Do not stop with Option Care Health. Use the screener to quickly surface fresh candidates, compare different angles, and line up your next few watchlist contenders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OPCH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com